Source - RNS
RNS Number : 1243B
Assura PLC
04 June 2019
 

4 June 2019

Assura plc

("the Company")

Notification of transaction by Persons Discharging Managerial Responsibilities ("PDMRs")

The Company announces that Jayne Cottam, CFO and PDMR, has purchased 47,200 Ordinary Shares of 10 pence each in the Company ("Ordinary Shares") in accordance with the shareholding requirement section of the remuneration policy. Following the purchase, the total beneficial interest of Jayne Cottam and her connected persons in the Ordinary shares is 90,743 Ordinary Shares. The shares were purchased in two tranches.

The Notification of Dealing Form for the PDMR can be found below.

This notification is made in accordance with the Market Abuse Regulation.

Notification of dealing form

1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

Name

 

Jayne Cottam

2

Reason for the notification

 

a)

Position/status

 

CFO

b)

Initial notification/ Amendment

 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

 

Assura plc

b)

LEI

 

21380026T19N2Y52XF72

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 10 pence each

 

 

 

 

 

GB00BVGBWW93

b)

Nature of the transaction

 

Share purchase for 63.54 pence per share

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£0.6354 GBP

 

8,400

d)

Aggregated information

 

-      Aggregated volume

 

-    Price

 

 

Aggregate Price

Aggregate Volume

Aggregate Total

 

£0.6354 GBP

 

 

8,400

 

£5,337.36 GBP

e)

Date of the transaction

 

4/06/2018

f)

Place of the transaction

 

XLON

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

Name

 

Jayne Cottam

2

Reason for the notification

 

a)

Position/status

 

CFO

b)

Initial notification/ Amendment

 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

 

Assura plc

b)

LEI

 

21380026T19N2Y52XF72

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 10 pence each

 

 

 

 

 

GB00BVGBWW93

b)

Nature of the transaction

 

Share purchase for 64.05 pence per share

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£0.6405 GBP

 

38,800

d)

Aggregated information

 

-      Aggregated volume

 

-    Price

 

 

Aggregate Price

Aggregate Volume

Aggregate Total

 

£0.6405 GBP

 

 

38,800

 

£24,851.40 GBP

e)

Date of the transaction

 

3/06/2018

f)

Place of the transaction

 

XLON

 

For more information, please contact:

 

Assura plc

 

Tel: 01925 420660

Orla Ball


David Purcell


 

Finsbury

 

Tel: 0207 251 3801

Gordon Simpson


 

Notes to Editors

Assura plc, a constituent of the FTSE 250 and the EPRA* indices, is a UK REIT and long-term investor in and developer of primary care property. The company, headquartered in Warrington, works with GPs, health professionals and the NHS to create outstanding spaces for health services in our communities. At 31 March 2019, Assura's property portfolio was valued at £1,979 million.

 

Further information is available at www.assuraplc.com

*EPRA is a registered trademark of the European Public Real Estate Association.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHGMGGVDDVGLZM